Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 ...

Medical bottles and a syringe are seen with the Novo Nordisk logo displayed on a screen in the background.

Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth ...

Novo Nordisk A/S named its head of international operations as chief executive officer after slumping weight-loss drug sales led to a profit warning that wiped $93 billion off its market value.

This story has been corrected as an earlier version said Wegovy AND Ozempic had been made available on prescription for weight loss in New Zealand but it is only Wegovy. Earlier this week ...